Similar articles for PMID: 18410043

Year	Number of Results
1981	1
1986	1
1997	1
2001	2
2002	4
2003	10
2004	17
2005	16
2006	6
2007	7
2008	8
2009	6
2010	3
2011	3
2012	4
2013	2
2014	4
2015	4
2016	3
2017	5
2018	3
2019	1
2020	5
2021	3
2022	1
2023	1
2024	0

1

Recognition and identification of UV-absorbing leachables in EPREX pre-filled syringes: an unexpected occurrence at a formulation-component interface.

Pang J, Blanc T, Brown J, Labrenz S, Villalobos A, Depaolis A, Gunturi S, Grossman S, Lisi P, Heavner GA. Pang J, et al. PDA J Pharm Sci Technol. 2007 Nov-Dec;61(6):423-32. PDA J Pharm Sci Technol. 2007. PMID: 18410043

2

The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.

Boven K, Stryker S, Knight J, Thomas A, van Regenmortel M, Kemeny DM, Power D, Rossert J, Casadevall N. Boven K, et al. Kidney Int. 2005 Jun;67(6):2346-53. doi: 10.1111/j.1523-1755.2005.00340.x. Kidney Int. 2005. PMID: 15882278 Free article.

3

Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery.

Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall N. Boven K, et al. Nephrol Dial Transplant. 2005 May;20 Suppl 3:iii33-40. doi: 10.1093/ndt/gfh1072. Nephrol Dial Transplant. 2005. PMID: 15824129

4

Epoetin-associated pure red cell aplasia: past, present, and future considerations.

McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, Casadevall N, Bennett CL. McKoy JM, et al. Transfusion. 2008 Aug;48(8):1754-62. doi: 10.1111/j.1537-2995.2008.01749.x. Epub 2008 May 14. Transfusion. 2008. PMID: 18482185 Free PMC article. Review.

5

Pure red-cell aplasia "epidemic"--mystery completely revealed?

Locatelli F, Del Vecchio L, Pozzoni P. Locatelli F, et al. Perit Dial Int. 2007 Jun;27 Suppl 2:S303-7. Perit Dial Int. 2007. PMID: 17556324 Review.

6

Interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions.

Villalobos AP, Gunturi SR, Heavner GA. Villalobos AP, et al. Pharm Res. 2005 Jul;22(7):1186-94. doi: 10.1007/s11095-005-5356-7. Epub 2005 Jul 22. Pharm Res. 2005. PMID: 16028020

7

Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout.

Mueller R, Karle A, Vogt A, Kropshofer H, Ross A, Maeder K, Mahler HC. Mueller R, et al. J Pharm Sci. 2009 Oct;98(10):3548-61. doi: 10.1002/jps.21672. J Pharm Sci. 2009. PMID: 19226629

8

Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework.

Jacob S, Nichols J, Macdougall IC, Qureshi Z, Chen B, Yang YT, Norris LB, Bennett CL. Jacob S, et al. Am J Ther. 2018 Nov/Dec;25(6):e670-e674. doi: 10.1097/MJT.0000000000000768. Am J Ther. 2018. PMID: 30169374

9

Pure red-cell aplasia and epoetin therapy.

Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N. Bennett CL, et al. N Engl J Med. 2004 Sep 30;351(14):1403-8. doi: 10.1056/NEJMoa040528. N Engl J Med. 2004. PMID: 15459301 Free article.

10

Epoetins: differences and their relevance to immunogenicity.

Haselbeck A. Haselbeck A. Curr Med Res Opin. 2003;19(5):430-2. doi: 10.1185/030079903125002063. Curr Med Res Opin. 2003. PMID: 13678480 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

113 results

Results by year